Regeneron Pharmaceuticals Stock
Regeneron Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Leonard S. Schleifer
- Employees
- 15,410
- Market cap
- $81.4 B
- IPO
- 02/04/1991
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise headquartered in Tarrytown, USA. The company focuses on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, used for various…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Regeneron Pharmaceuticals stock: price history
1D
-0.7%
1W
+5.9%
1M
+2.1%
6M
+5.4%
YTD
+2.4%
1Y
+38.9%
2Y
-21.6%
5Y
+42.9%
10Y
+112.7%
Next earnings date
Next earnings date
30/10/2026 (in 13 days)
Volatility around earnings
~13% weaker price swings than usual
Ask the agents about Regeneron Pharmaceuticals
Analyst assessment of Regeneron Pharmaceuticals
PRICE TARGET LOW
US$750.00
CONSENSUS
US$856.25
MEDIAN
US$852.00
PRICE TARGET HIGH
US$1,030.00
0
STRONG BUY
35
BUY
14
HOLD
0
SELL
0
STRONG SELL
49
TOTAL · Buy
As of: 15/10/2026
Regeneron Pharmaceuticals stock metrics
P/E
18.88
P/B
2.58
EV/EBITDA
14.08
RETURN ON EQUITY
4.1%
NET MARGIN
30.2%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.5%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.2%
FLOAT SHARES
99,067,402
AVG. DAILY VOLUME (30D)
719,594
Insider transactions (SEC)
MURPHY ANDREW J
MURPHY ANDREW J
MURPHY ANDREW J
MURPHY ANDREW J
MURPHY ANDREW J
Institutional holders
Dividends
Comparable stocks
Frequently asked questions about Regeneron Pharmaceuticals stock
What does Regeneron Pharmaceuticals do?
Regeneron Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Leonard S. Schleifer, the company employs around 15,410 people.
The IPO was on 02/04/1991; the stock trades on NASDAQ under the ticker REGN.
What do analysts say about Regeneron Pharmaceuticals stock?
49 analysts rate the stock, the consensus is Buy (as of 15/10/2026).
The average price target is US$856.25, ranging from US$750.00 to US$1,030.00, with a median of US$852.00.
This is an external assessment, not a statement by Market Jury.
When does Regeneron Pharmaceuticals report next?
The next earnings date is 30/10/2026.
Around past earnings, price swings were roughly -13% stronger than usual.
Does Regeneron Pharmaceuticals pay a dividend?
Yes. The last dividend was US$0.94 per share, ex-date 18/08/2026, paid on 31/08/2026.
The dividend yield is 0.5% (as of 30/06/2026).
Which stocks are comparable to Regeneron Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences, Summit Therapeutics and Halozyme Therapeutics.
How can I get Regeneron Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Regeneron Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.